Quantitative systems pharmacology model predictions for efficacy of atezolizumab and nab-paclitaxel in triple-negative breast cancer

Código QR

Quantitative systems pharmacology model predictions for efficacy of atezolizumab and nab-paclitaxel in triple-negative breast cancer

Guardado en:

Detalles Bibliográficos
Autores principales:	Leisha A Emens, Huilin Ma, Hanwen Wang, Richard J Sové, Aleksander S Popel
Formato:	article
Lenguaje:	EN
Publicado:	BMJ Publishing Group 2021
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/46662a33a2a04b4e89ceddf01ba602a9
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Correction: Quantitative systems pharmacology model predictions for efficacy of atezolizumab and nab-paclitaxel in triple-negative breast cancer
Publicado: (2021)

Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer
por: Julia Foldi, et al.
Publicado: (2021)

Cisplatin improves antitumor activity of weekly nab-paclitaxel in patients with metastatic breast cancer
por: Sun S, et al.
Publicado: (2014)

Phase II trail of nab-paclitaxel in metastatic breast cancer patients with visceral metastases
por: Yizhao Xie, et al.
Publicado: (2021)

Cellular uptake mechanism and comparative evaluation of antineoplastic effects of paclitaxel–cholesterol lipid emulsion on triple-negative and non-triple-negative breast cancer cell lines
por: Ye J, et al.
Publicado: (2016)

nab-paclitaxel/carboplatin induction in squamous NSCLC: longitudinal quality of life while on chemotherapy
por: Thomas M, et al.
Publicado: (2017)

Weekly Paclitaxel given concurrently with Durvalumab has a favorable safety profile in triple-negative metastatic breast cancer
por: Hazem Ghebeh, et al.
Publicado: (2021)

Phase II trial of weekly nab-paclitaxel and carboplatin treatment with or without trastuzumab as nonanthracycline neoadjuvant chemotherapy for locally advanced breast cancer
por: Huang L, et al.
Publicado: (2015)

Dramatic Reduction of Distant Pancreatic Metastases Using Local Light Activation of Verteporfin with Nab-Paclitaxel
por: Michael Pigula, et al.
Publicado: (2021)

Identifying the Effect of Ursolic Acid Against Triple-Negative Breast Cancer: Coupling Network Pharmacology With Experiments Verification
por: Yubao Zhang, et al.
Publicado: (2021)

Quantitative proteomic landscape of metaplastic breast carcinoma pathological subtypes and their relationship to triple-negative tumors
por: Sabra I. Djomehri, et al.
Publicado: (2020)

Risk factors for severe neutropenia in pancreatic cancer patients treated with gemcitabine/nab-paclitaxel combination therapy.
por: Genta Ito, et al.
Publicado: (2021)

Biochemical and genetic predictors of overall survival in patients with metastatic pancreatic cancer treated with capecitabine and nab-paclitaxel
por: Daniela Bianconi, et al.
Publicado: (2017)

Differential cytotoxic and radiosensitizing effects of silver nanoparticles on triple-negative breast cancer and non-triple-negative breast cells
por: Swanner J, et al.
Publicado: (2015)

A retrospective analysis of safety and efficacy of weekly nab-paclitaxel as second-line chemotherapy in elderly patients with advanced squamous non-small-cell lung carcinoma
por: Jin F, et al.
Publicado: (2016)

Targeting nucleotide metabolism enhances the efficacy of anthracyclines and anti-metabolites in triple-negative breast cancer
por: Craig Davison, et al.
Publicado: (2021)

A triple negative breast cancer: what it is not!
por: Katakkar SB
Publicado: (2012)

Triple negative breast cancer: an Indian perspective
por: Akhtar M, et al.
Publicado: (2015)

Molecular characteristics and metastasis predictor genes of triple-negative breast cancer: a clinical study of triple-negative breast carcinomas.
por: Wen-Hung Kuo, et al.
Publicado: (2012)

Species difference in paclitaxel disposition correlated with poor pharmacological efficacy translation from mice to humans
por: Li YF, et al.
Publicado: (2018)

BRCA2 mutations and triple-negative breast cancer.
por: Peter Meyer, et al.
Publicado: (2012)

Triple-negative breast cancer: treatment challenges and solutions
por: Collignon J, et al.
Publicado: (2016)

Opportunities for metastatic triple negative breast cancer therapy
por: Inna P. Ganshina, et al.
Publicado: (2021)

Antiangiogenic therapy for breast cancer with triple negative phenotype
por: Inna P. Ganshina, et al.
Publicado: (2021)

Nab-paclitaxel-associated photosensitivity: report in a woman with non-small cell lung cancer and review of taxane-related photodermatoses
por: Bryce D. Beutler, et al.
Publicado: (2015)

First‐line nab‐paclitaxel plus carboplatin for patients with advanced non‐small cell lung cancer: Results of the NEPTUN study
por: Tobias Dechow, et al.
Publicado: (2021)

Encapsulating Halofuginone Hydrobromide in TPGS Polymeric Micelles Enhances Efficacy Against Triple-Negative Breast Cancer Cells
por: Zuo R, et al.
Publicado: (2021)

Conversion Surgery for Advanced Thoracic SMARCA4-Deficient Undifferentiated Tumor With Atezolizumab in Combination With Bevacizumab, Paclitaxel, and Carboplatin Treatment: A Case Report
por: Kei Kunimasa, MD, PhD, et al.
Publicado: (2021)

Molecular-Genetic Portrait of Breast Cancer with Triple Negative Phenotype
por: Marina K. Ibragimova, et al.
Publicado: (2021)

Molecular heterogeneity in adjacent cells in triple-negative breast cancer
por: Huebschman ML, et al.
Publicado: (2015)

Next generation of anti-PD-L1 Atezolizumab with enhanced anti-tumor efficacy in vivo
por: Maohua Li, et al.
Publicado: (2021)

Quantum dot-based immunofluorescent imaging and quantitative detection of TOP2A and prognostic value in triple-negative breast cancer
por: Zheng H, et al.
Publicado: (2016)

Protein truncating variants in FANCM and risk for ER-negative/triple negative breast cancer
por: Paolo Peterlongo, et al.
Publicado: (2021)

Repositioning metformin and propranolol for colorectal and triple negative breast cancers treatment
por: L. E. Anselmino, et al.
Publicado: (2021)

A new immunochemical strategy for triple-negative breast cancer therapy
por: Chih-Wei Lin, et al.
Publicado: (2021)

Peptide density targets and impedes triple negative breast cancer metastasis
por: Daxing Liu, et al.
Publicado: (2018)

Current advances in biomarkers for targeted therapy in triple-negative breast cancer
por: Fleisher B, et al.
Publicado: (2016)

Triple-Negative Breast Cancer Histological Subtypes with a Favourable Prognosis
por: Gábor Cserni, et al.
Publicado: (2021)

Novel therapeutic strategies for patients with metastatic triple-negative breast cancer
por: Inna P. Ganshina, et al.
Publicado: (2021)

Non-Coding RNAs Associated With Radioresistance in Triple-Negative Breast Cancer
por: Alberto Aranza-Martínez, et al.
Publicado: (2021)